A clinical study to evaluate HF10 therapy using surgical leads

Submission date	Recruitment status	Prospectively registered
21/10/2019	No longer recruiting	[] Protocol
Registration date	Overall study status	Statistical analysis plan
22/10/2019	Completed	[] Results
Last Edited	Condition category	Individual participant data
22/10/2019	Signs and Symptoms	[_] Record updated in last year

Plain English summary of protocol

Background and study aims

Spinal cord stimulation (SCS) involves implanting a device that delivers small electrical fields to the spinal cord to provide pain relief in patients with chronic (long-term), intractable (hard to control) back and leg pain. Significant leg pain relief has been reported with traditional SCS which uses a low frequency (<1200 Hz), but there is limited long-term data supporting the use of low-frequency SCS in predominant back pain patients. Recent studies testing SCS using a frequency of 10 kHz (HF10 Therapy™) have shown that this treatment is effective and safe in patients with both back and leg pain. The results from these studies demonstrated that these patients had significant pain relief up to 24 months. The decreased pain in both back and leg were consistent throughout the studies with improvements in functional capacity with no perception of paresthesia (a burning or prickling sensation). The aim of this study is to test the performance of HF10 therapy with the surgical lead worldwide in patients with back and/or leg pain, as per centers' routine practice.

Who can participate?

Patients aged over 18 with chronic, intractable back and/or leg pain

What does the study involve?

Participants undergo Spinal Cord Stimulation (SCS) at 10 kHz (HF10 therapy) as per the center's usual practice. SCS involves the surgical placement of a surgical lead (which looks like a thin wire) into a small area near the spinal cord. Electrical stimulation is delivered through this wire by a small, battery-operated, rechargeable SCS implanted generator. Each patient is followed for 12 months after device activation. The participants attend regular clinic visits to complete questionnaires and to provide feedback on their pain. Successfully treated participants get a permanent device implanted as per the center's routine clinical practice.

What are the possible benefits and risks of participating?

Participants may benefit from the SCS system to relieve their pain. There are no direct risks of taking part in this study, although the general risks of having a spinal stimulation device in place apply.

Where is the study run from? Up to 40 pain centers in the USA and Europe

When is the study starting and how long is it expected to run for? October 2018 to December 2021

Who is funding the study? Nevro Corp (USA)

Who is the main contact? Brad Gliner gliner@nevro.com

Contact information

Type(s) Public

Contact name

Mr Brad Gliner

Contact details

1800 Bridge Parkway Redwood City United States of America CA 94065 0061502510005 gliner@nevro.com

Type(s)

Scientific

Contact name

Mr Brad Gliner

Contact details

1800 Bridge Parkway Redwood City United States of America CA 94065 0016502510005 gliner@nevro.com

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers CA2018-4 INT SURPASS

Study information

Scientific Title

A prospective observational multicenter study of HF10 therapy using surgical leads

Acronym SURPASS

Study objectives

The purpose of this study is to assess the clinical performance of HF10 therapy delivered to the spinal cord through SURPASS[™] surgical leads in subjects with chronic, intractable, back and/or leg pain of neuropathic origin.

Ethics approval required

Old ethics approval format

Ethics approval(s)

USA: Approved 29/11/2018, Western Institutional Review Board, 1019 39th Avenue SE Suite 120, Puyallup, WA 98374-2115, USA; Tel: +1 (360) 252-2500, +1 (800) 562-4789; Email: clientservices@wirb.com), IRB Tracking Number: 20183112 Belgium: Approved 14/05/2019, AZ Delta, Commissie voor Medische Ethiek (Rode Kruisstraat 20, 8800 Roeselare, Belgium; Tel: +32 (0)56 52 22 31; Email: sigrid.deneve@azdelta.be), ref. 19019

Study design

Multi-center prospective observational clinical study

Primary study design Observational

Secondary study design Case series

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Chronic, intractable, back and/or leg pain of neuropathic origin

Interventions

As part of their standard care, participants undergo a trial (temporary evaluation period) of Spinal Cord Stimulation (SCS) at 10 kHz (HF10 Therapy) as per the center's usual practice and following this, those for whom the trial treatment was successful have a permanent device implanted as per center's routine clinical practice.

Following device activation, participants are followed for a period of 12 months. The participants attend regular clinic visits, at 3, 6 and 12 months, to complete questionnaires, and to provide feedback on their pain, quality of life, disability, health status, satisfaction and work status. At these visits, the physicians will take assessments from the participants such as pain evaluation, medication usage and side effects (if any).

Intervention Type

Device

Phase Not Applicable

Primary outcome measure

Responder rate at 3 months (a responder is defined as a subject who experiences ≥30% pain reduction compared to baseline as assessed by NRS & improvement in health status per the patient global impression of change questionnaire)

Secondary outcome measures

1. Pain is measured using the numerical rating scale (NRS) at baseline, end of trial, 3, 6 and 12 months

2. Disability is measured using the Oswestry Disability Index (ODI) at baseline, 3, 6 and 12 months

- 3. Quality of life is measured using the EQ-5D-5L at baseline, 3, 6 and 12 months
- 4. Opioid intake is measured using a medication log at baseline, end of trial, 3, 6, 12 months

5. Health status is measured using the patient/physician global impression of change guestionnaire at end of trial, 3, 6, 12 months

6. Participant satisfaction with the therapy is measured using the subject satisfaction questionnaire at 3,6 and 12 months

Overall study start date

01/10/2018

Completion date

31/12/2023

Eligibility

Key inclusion criteria

1. Have chronic intractable back pain and/or leg pain of neuropathic origin, as determined by the physician

2. An appropriate candidate for spinal cord stimulation and/or surgical lead placement as determined by the physician

3. Already scheduled for either a commercial trial with Nevro or a permanent implant of the Senza system (with surgical lead only)

4. Be 18 years of age or older at the time of enrollment

5. Be able to read and understand the Patient Informed Consent Form

6. Be willing and capable of giving informed consent

Participant type(s)

Patient

Age group Adult

Lower age limit

18 Years

Sex Both

Target number of participants Up to 339 participants will be enrolled

Key exclusion criteria

1. Contraindicated for surgical lead placement and/or spinal cord stimulation; physician should reference labeling for precautions, warnings and indications

Date of first enrolment 06/05/2019

Date of final enrolment 31/12/2021

Locations

Countries of recruitment Belgium

United States of America

Study participating centre AZ Delta Roeselare Belgium 8800

Study participating centre Albany Medical College Albany United States of America NY 12208 Study participating centre Neuroscience Group 1305 W American Dr Neenah Wisconsin United States of America 54956

Sponsor information

Organisation Nevro Corp

Sponsor details 1800 Bridge Parkway

Redwood City United States of America CA 94065 001650251005 gliner@nevro.com

Sponsor type Industry

ROR https://ror.org/02xcxe208

Funder(s)

Funder type Industry

Funder Name Nevro Corp

Results and Publications

Publication and dissemination plan

1. Planned presentation of results to international congresses from the start of 2021

2. Planned publication in a peer-reviewed journal from the start of 2022

3. Additional documents (such as study protocol, statistical analysis plan, other) will be available upon request

Intention to publish date

31/12/2021

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Brad Gliner (gliner@nevro.com).

IPD sharing plan summary

Available on request